CV Form 4: Director Julia Gouw Receives 2,887 RSUs with Year‑End Vesting
Rhea-AI Filing Summary
CapsoVision insider report: Julia S. Gouw, a director of CapsoVision, Inc. (CV), was granted 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents the contingent right to receive one share of the issuer's common stock, and the RSUs are scheduled to vest on December 31, 2025. Following the reported transaction the filing shows 2,887 shares beneficially owned directly attributable to these RSUs. The RSUs have an indicated price of $0 in the filing, and the Form 4 was signed by an attorney-in-fact on behalf of Ms. Gouw on 09/17/2025. No other transactions or derivative securities are reported in this filing.
Positive
- 2,887 RSUs granted to a director aligns the director's interests with shareholders through equity ownership
- Clear vesting date: RSUs scheduled to vest on December 31, 2025, providing transparency on timing of share issuance
Negative
- None.
Insights
TL;DR: Director received time‑based RSUs that align her economic incentives with shareholders, vesting at year-end.
The grant of 2,887 RSUs to a director is a routine equity‑based compensation mechanism that ties the director's interests to stock performance through a defined vesting date of December 31, 2025. The Form 4 discloses a direct beneficial ownership of 2,887 shares following the grant. Because the filing shows a single non‑derivative award and no disposals or exercises, the event appears administrative and typical for board compensation. Materiality is likely low absent additional context on company size or outstanding share count, which are not provided in this filing.
TL;DR: A modest RSU award was recorded; vesting schedule is explicit but financial impact is not quantifiable from this form alone.
The Form 4 reports 2,887 RSUs granted on 09/15/2025 that vest on 12/31/2025, each converting to one share of common stock. The filing lists a $0 price, consistent with standard RSU awards that convert to shares rather than requiring purchase. The document does not state grant date fair value, total outstanding shares, or how this award compares to prior grants, so compensation expense and dilution impact cannot be determined from the filing alone.